Biodexa Pharmaceuticals sees cash runway into 1Q26 As of May 29, 2025, the Company had access to the following cash resources: Cash at bank $5.7M; Cash in escrow for eRapa Phase 3 program $4.4M ...

Omnicell, Inc. (NASDAQ:OMCL) has reported its fiscal year and fourth quarter 2024 results, revealing a strong performance in the final quarter. The company's total revenues for the fourth quarter of ...

At close: May 29 at 4:00:01 PM EDT ...

Omnicell Inc provides automation and business analytics software solutions for patient-centric medication and supplies management across the entire healthcare continuum, from the acute care hospital ...